Financial reports
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
10-K
2021 FY
Annual report
1 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Apr 24
8-K
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
5 Mar 24
8-K
Seres Therapeutics Announces the Appointment of Marella Thorell As Chief Financial Officer and the Retirement of David Arkowitz
26 Feb 24
8-K
Other Events
30 Jan 24
8-K
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
10 Jan 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
2 Jan 24
8-K
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
2 Nov 23
8-K
Departure of Directors or Certain Officers
4 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
5 Mar 24
S-3
Shelf registration
8 Aug 23
S-8
Registration of securities for employees
7 Mar 23
S-8
Registration of securities for employees
30 Dec 22
424B5
Prospectus supplement for primary offering
30 Jun 22
POS AM
Prospectus update (post-effective amendment)
4 May 22
POS AM
Prospectus update (post-effective amendment)
1 Mar 22
S-8
Registration of securities for employees
1 Mar 22
POSASR
Automatic shelf registration (post-effective amendment)
1 Mar 22
424B5
Prospectus supplement for primary offering
21 May 21
Proxies
DEF 14A
Definitive proxy
5 Mar 24
PRE 14A
Preliminary proxy
23 Feb 24
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEFA14A
Additional proxy soliciting materials
30 Apr 20
Other
EFFECT
Notice of effectiveness
16 Aug 23
UPLOAD
Letter from SEC
11 Aug 23
CORRESP
Correspondence with SEC
11 Aug 23
EFFECT
Notice of effectiveness
6 May 22
EFFECT
Notice of effectiveness
19 Mar 20
CORRESP
Correspondence with SEC
16 Mar 20
UPLOAD
Letter from SEC
13 Mar 20
CT ORDER
Confidential treatment order
15 Apr 19
EFFECT
Notice of effectiveness
24 Mar 17
CORRESP
Correspondence with SEC
22 Mar 17